Evaluation of Moxifloxacin-Containing Regimens in Pathologically Distinct Murine Tuberculosis Models

In the recently concluded REMox-TB trial, two 4-month moxifloxacin-containing regimens did not meet the criteria for noninferiority compared to the current 6-month first-line regimen to treat tuberculosis (TB). Despite the disappointing result, this phase 3 clinical trial provides a rare opportunity...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Antimicrob Agents Chemother
Egile Nagusiak: Li, Si-Yang, Irwin, Scott M., Converse, Paul J., Mdluli, Khisi E., Lenaerts, Anne J., Nuermberger, Eric L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2015
Gaiak:
Experimental Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4468727/
https://ncbi.nlm.nih.gov/pubmed/25918146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00105-15
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak